283 related articles for article (PubMed ID: 33975008)
1. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening.
Arbyn M; Simon M; Peeters E; Xu L; Meijer CJLM; Berkhof J; Cuschieri K; Bonde J; Ostrbenk Vanlencak A; Zhao FH; Rezhake R; Gultekin M; Dillner J; de Sanjosé S; Canfell K; Hillemanns P; Almonte M; Wentzensen N; Poljak M
Clin Microbiol Infect; 2021 Aug; 27(8):1083-1095. PubMed ID: 33975008
[TBL] [Abstract][Full Text] [Related]
2. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
Arbyn M; Snijders PJ; Meijer CJ; Berkhof J; Cuschieri K; Kocjan BJ; Poljak M
Clin Microbiol Infect; 2015 Sep; 21(9):817-26. PubMed ID: 25936581
[TBL] [Abstract][Full Text] [Related]
3. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis.
Arbyn M; Simon M; de Sanjosé S; Clarke MA; Poljak M; Rezhake R; Berkhof J; Nyaga V; Gultekin M; Canfell K; Wentzensen N
Lancet Oncol; 2022 Jul; 23(7):950-960. PubMed ID: 35709810
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework.
Dhillon SK; Oštrbenk Valenčak A; Xu L; Poljak M; Arbyn M
J Clin Microbiol; 2021 May; 59(6):. PubMed ID: 33731413
[TBL] [Abstract][Full Text] [Related]
5. VALGENT: A protocol for clinical validation of human papillomavirus assays.
Arbyn M; Depuydt C; Benoy I; Bogers J; Cuschieri K; Schmitt M; Pawlita M; Geraets D; Heard I; Gheit T; Tommasino M; Poljak M; Bonde J; Quint W
J Clin Virol; 2016 Mar; 76 Suppl 1():S14-S21. PubMed ID: 26522865
[TBL] [Abstract][Full Text] [Related]
6. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.
Heideman DAM; Xu L; Hesselink AT; Doorn S; Ejegod DM; Pedersen H; Quint WGV; Bonde J; Arbyn M
J Clin Virol; 2019 Dec; 121():104201. PubMed ID: 31629967
[TBL] [Abstract][Full Text] [Related]
7. Validation of EUROArray HPV test using the VALGENT framework.
Viti J; Poljak M; Oštrbenk A; Bhatia R; Alcañiz Boada E; Cornall AM; Cuschieri K; Garland S; Xu L; Arbyn M
J Clin Virol; 2018 Nov; 108():38-42. PubMed ID: 30223253
[TBL] [Abstract][Full Text] [Related]
8. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
[TBL] [Abstract][Full Text] [Related]
9. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework.
Ejegod DM; Hansen M; Christiansen IK; Pedersen H; Quint W; Xu L; Arbyn M; Bonde J
J Clin Virol; 2020 Jul; 128():104336. PubMed ID: 32446166
[TBL] [Abstract][Full Text] [Related]
10. Concordance of Anyplex™ II HPV HR assays with reference HPV assays in cervical cancer screening: Systematic review.
Biazin H
J Virol Methods; 2022 Mar; 301():114435. PubMed ID: 34919974
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
Oštrbenk A; Xu L; Arbyn M; Poljak M
J Clin Microbiol; 2018 Nov; 56(11):. PubMed ID: 30209184
[TBL] [Abstract][Full Text] [Related]
12. Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
Oštrbenk Valenčak A; Šterbenc A; Seme K; Poljak M
J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31666369
[TBL] [Abstract][Full Text] [Related]
13. Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework.
Heard I; Cuschieri K; Geraets DT; Quint W; Arbyn M
J Clin Virol; 2016 Aug; 81():6-11. PubMed ID: 27262102
[TBL] [Abstract][Full Text] [Related]
14. VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples.
Arbyn M; Peeters E; Benoy I; Vanden Broeck D; Bogers J; De Sutter P; Donders G; Tjalma W; Weyers S; Cuschieri K; Poljak M; Bonde J; Cocuzza C; Zhao FH; Van Keer S; Vorsters A
J Clin Virol; 2018 Oct; 107():52-56. PubMed ID: 30195193
[TBL] [Abstract][Full Text] [Related]
15. Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening.
Akbari A; Vanden Broeck D; Benoy I; Padalko E; Bogers J; Arbyn M
Virol J; 2018 Oct; 15(1):166. PubMed ID: 30373616
[TBL] [Abstract][Full Text] [Related]
16. Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests).
Cuschieri K; Geraets D; Cuzick J; Cadman L; Moore C; Vanden Broeck D; Padalko E; Quint W; Arbyn M
J Clin Microbiol; 2016 Sep; 54(9):2337-42. PubMed ID: 27385707
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.
Bonde JH; Pedersen H; Quint W; Xu L; Arbyn M; Ejegod DM
J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31723012
[TBL] [Abstract][Full Text] [Related]
18. Using the VALGENT-3 framework to assess the clinical and analytical performance of the RIATOL qPCR HPV genotyping assay.
Benoy I; Xu L; Vanden Broeck D; Poljak M; Oštrbenk Valenčak A; Arbyn M; Bogers J
J Clin Virol; 2019 Nov; 120():57-62. PubMed ID: 31569008
[TBL] [Abstract][Full Text] [Related]
19. Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework.
Xu L; Oštrbenk Valenčak A; Poljak M; Arbyn M
J Clin Microbiol; 2020 May; 58(6):. PubMed ID: 32245832
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
Xu L; Oštrbenk A; Poljak M; Arbyn M
J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
